Tags: 
Pfizer, a pharmaceutical company, in partnership with BioNTech has reported that its lead vaccine candidates has shown promising results in protecting monkeys against coronavirus infections.
Pfizer ‘s experimental vaccine is different from other vaccine candidates. This is in an mRNA format, which should allow for a better migration of the viral gene into the cell cytoplasm, thus a better production of the viral protein able to stimulate the animal immune system.
In a recent published study it was reported that the vaccine, produced antibodies that neutralized SARS-CoV-2. Macaques were given one vaccine shot together with a booster shot. Vaccinated macaques were protected from the coronavirus infection, compared to the unvaccinated animals which became infected. The study also demonstrated that the vaccine initiated an immune response via the activation of T cells in the macaques, which also contributed to the antiviral effect.
Source Article: Fierce Biotech: Pfizer, BioNTech report ‘strong’ immune response in animals to COVID-19 mRNA vaccine candidate
Vaccines and the Immune Response: How Vaccines Work
#vaccine, # clinical Research, # Covid 19, # immunology, # medical research, # drug development, #BBCR
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.